Cargando…

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain

PURPOSE: To determine the clinical and economic impact of inhaled corticosteroid (ICS) withdrawal in Spanish patients with COPD receiving triple therapy (TT) with ICS, long-acting β(2)-agonist (LABA), and long-acting muscarinic antagonist (LAMA). PATIENTS AND METHODS: This was an observational, retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Neches García, Victoria, Vallejo-Aparicio, Laura Amanda, Ismaila, Afisi S, Sicras-Mainar, Antoni, Sicras-Navarro, Aram, González, Cruz, Cuervo, Rafael, Shukla, Soham, García-Peñuela, Marcos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464437/
https://www.ncbi.nlm.nih.gov/pubmed/36101793
http://dx.doi.org/10.2147/COPD.S367708
_version_ 1784787581685202944
author Neches García, Victoria
Vallejo-Aparicio, Laura Amanda
Ismaila, Afisi S
Sicras-Mainar, Antoni
Sicras-Navarro, Aram
González, Cruz
Cuervo, Rafael
Shukla, Soham
García-Peñuela, Marcos
author_facet Neches García, Victoria
Vallejo-Aparicio, Laura Amanda
Ismaila, Afisi S
Sicras-Mainar, Antoni
Sicras-Navarro, Aram
González, Cruz
Cuervo, Rafael
Shukla, Soham
García-Peñuela, Marcos
author_sort Neches García, Victoria
collection PubMed
description PURPOSE: To determine the clinical and economic impact of inhaled corticosteroid (ICS) withdrawal in Spanish patients with COPD receiving triple therapy (TT) with ICS, long-acting β(2)-agonist (LABA), and long-acting muscarinic antagonist (LAMA). PATIENTS AND METHODS: This was an observational, retrospective study of BIG-PAC database medical records. Patients aged ≥40 years receiving TT from 2016 to 2018 were followed for 1 year. Two cohorts were identified: patients continuing TT (ICS+LABA+LAMA), and patients receiving TT with ICS withdrawn (LABA+LAMA). Variables included medication, exacerbations (moderate and severe), pneumonia, mortality, health resource use (HRU), and cost per patient/year. Cohorts were compared using propensity score matching (PSM). Multivariate statistical analysis using analysis of covariance and Cox proportional risks was conducted. RESULTS: Of 6541 patients included, 5740 (87.8%) continued TT and 801 (12.2%) had ICS withdrawn. Patients with ICS withdrawal were younger, had lower disease burden, higher ICS doses, and more exacerbations compared with those continuing ICS. PSM matched 795 patients in each cohort. Mean age was 68.5 years (SD: 11.2), 69.9% were male, and mean Charlson index was 2.0. Patients with ICS withdrawal had more total exacerbations in the 12 months following withdrawal compared with patients continuing TT (36.6% vs 31.4%; p=0.030). No significant differences were found for pneumonia (3.3% vs 3.6%; p=0.583) and mortality (9.9% vs 7.5%; p=0.092). Median time to first exacerbation was shorter in patients with ICS withdrawal compared with those continuing ICS (HR: 0.69, 95% CI: 0.57–0.83; p<0.001). Mean health cost per patient/year among patients with ICS withdrawal was higher than those continuing TT (€2993 vs €2130; p<0.001). CONCLUSION: ICS withdrawal in patients with COPD receiving TT was associated with increased exacerbations, HRU, and costs compared with continuing TT, with health and economic impacts on patients and the Spanish National Healthcare System, respectively. Pneumonia and mortality rates were similar between groups.
format Online
Article
Text
id pubmed-9464437
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94644372022-09-12 Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain Neches García, Victoria Vallejo-Aparicio, Laura Amanda Ismaila, Afisi S Sicras-Mainar, Antoni Sicras-Navarro, Aram González, Cruz Cuervo, Rafael Shukla, Soham García-Peñuela, Marcos Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: To determine the clinical and economic impact of inhaled corticosteroid (ICS) withdrawal in Spanish patients with COPD receiving triple therapy (TT) with ICS, long-acting β(2)-agonist (LABA), and long-acting muscarinic antagonist (LAMA). PATIENTS AND METHODS: This was an observational, retrospective study of BIG-PAC database medical records. Patients aged ≥40 years receiving TT from 2016 to 2018 were followed for 1 year. Two cohorts were identified: patients continuing TT (ICS+LABA+LAMA), and patients receiving TT with ICS withdrawn (LABA+LAMA). Variables included medication, exacerbations (moderate and severe), pneumonia, mortality, health resource use (HRU), and cost per patient/year. Cohorts were compared using propensity score matching (PSM). Multivariate statistical analysis using analysis of covariance and Cox proportional risks was conducted. RESULTS: Of 6541 patients included, 5740 (87.8%) continued TT and 801 (12.2%) had ICS withdrawn. Patients with ICS withdrawal were younger, had lower disease burden, higher ICS doses, and more exacerbations compared with those continuing ICS. PSM matched 795 patients in each cohort. Mean age was 68.5 years (SD: 11.2), 69.9% were male, and mean Charlson index was 2.0. Patients with ICS withdrawal had more total exacerbations in the 12 months following withdrawal compared with patients continuing TT (36.6% vs 31.4%; p=0.030). No significant differences were found for pneumonia (3.3% vs 3.6%; p=0.583) and mortality (9.9% vs 7.5%; p=0.092). Median time to first exacerbation was shorter in patients with ICS withdrawal compared with those continuing ICS (HR: 0.69, 95% CI: 0.57–0.83; p<0.001). Mean health cost per patient/year among patients with ICS withdrawal was higher than those continuing TT (€2993 vs €2130; p<0.001). CONCLUSION: ICS withdrawal in patients with COPD receiving TT was associated with increased exacerbations, HRU, and costs compared with continuing TT, with health and economic impacts on patients and the Spanish National Healthcare System, respectively. Pneumonia and mortality rates were similar between groups. Dove 2022-09-07 /pmc/articles/PMC9464437/ /pubmed/36101793 http://dx.doi.org/10.2147/COPD.S367708 Text en © 2022 Neches García et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Neches García, Victoria
Vallejo-Aparicio, Laura Amanda
Ismaila, Afisi S
Sicras-Mainar, Antoni
Sicras-Navarro, Aram
González, Cruz
Cuervo, Rafael
Shukla, Soham
García-Peñuela, Marcos
Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
title Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
title_full Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
title_fullStr Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
title_full_unstemmed Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
title_short Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
title_sort clinical and economic impact of long-term inhaled corticosteroid withdrawal in patients with chronic obstructive pulmonary disease treated with triple therapy in spain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464437/
https://www.ncbi.nlm.nih.gov/pubmed/36101793
http://dx.doi.org/10.2147/COPD.S367708
work_keys_str_mv AT nechesgarciavictoria clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT vallejoapariciolauraamanda clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT ismailaafisis clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT sicrasmainarantoni clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT sicrasnavarroaram clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT gonzalezcruz clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT cuervorafael clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT shuklasoham clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain
AT garciapenuelamarcos clinicalandeconomicimpactoflongterminhaledcorticosteroidwithdrawalinpatientswithchronicobstructivepulmonarydiseasetreatedwithtripletherapyinspain